Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-01-09 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
APPOINTMENT OF INDEPENDENT DIRECTOR&#x3b; ESTABLISHMENT OF COMMERCIAL COMMITTEE&#x3b; AND CHANGE OF COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 100% confidence The document is an announcement from Zai Lab Limited regarding the appointment of an independent director, the establishment of a new Commercial Committee, and changes in the composition of board committees. It includes detailed biographical information about the new director, his compensation, and committee roles. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content focuses on board and management changes, which aligns with the category for announcements about changes in the company's board of directors or senior management. Therefore, the document fits the Board/Management Information (MANG) category.
2023-01-09 English
OVERSEAS REGULATORY ANNOUNCEMENT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission, which is a current report used to announce significant events. The content specifically details the appointment of a new independent director, Michel Vounatsos, to the company's board, including his background, compensation, and committee assignments. There is no financial data or comprehensive report content such as annual or quarterly financial statements. The document is an announcement of a board/management change, not a full report or earnings release. Therefore, it fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed information about the director appointment, supporting a high confidence level.
2023-01-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return concerning movements in securities, specifically focusing on share capital, issued shares, share options, and related confirmations. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, particularly Chapter 19B. The content includes detailed tables of share capital, share options, and confirmations about the issuance and authorization of shares. There is no indication that this is an annual or quarterly financial report, earnings release, or management discussion. Instead, it is a regulatory filing reporting on share capital movements and share option schemes for a specific month (December 2022). The document is not a simple announcement or a brief summary but a formal regulatory submission with detailed data. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-01-06 English
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission by Zai Lab Limited. It announces the positive results of the LUNAR study related to a clinical trial for non-small cell lung cancer treatment. The document includes a press release as an exhibit and discusses the study's outcomes and future plans for regulatory filings. There are no financial statements or detailed financial data presented; rather, it is an event-driven announcement about a clinical trial milestone and licensing agreement. This type of filing is categorized as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release or annual report. The document is substantive and not merely a brief announcement or certification, so it is not an RPA or a certification filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-01-06 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of share options and restricted share units under the 2022 Equity Incentive Plan. It details the number of options and restricted shares granted, exercise prices, vesting periods, and other terms related to equity compensation. The document references compliance with Listing Rules and provides specific data about the grants. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory certification or voting result. The content clearly pertains to share-based compensation grants, which falls under announcements related to share issues or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change announcement (SHA). The document length and detail confirm it is not a brief notice or a report publication announcement, and it is not a director's dealing report since it concerns grants to an employee who is not a director or substantial shareholder.
2023-01-03 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options under the company's 2022 Equity Incentive Plan. It details the number of options granted, exercise price, vesting period, and other terms related to the share options. There is no financial performance data, no discussion of management or board changes, no voting results, and no mention of a report being attached or published. The content is focused on the issuance of share options, which is a capital-related event. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is 5563 characters, which is sufficient for a detailed announcement rather than a brief notice or a report publication announcement.
2022-12-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.